Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Introduction Direct oral anticoagulant (DOAC) agents are established as the anticoagulation
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …

Background Atrial fibrillation (AF) and obesity affect over 60 and 650 million people,
respectively. Aim This study aimed to explore clinician practices, beliefs, and attitudes …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …